REGENXBIO (RGNX) Expected to Announce Quarterly Earnings on Monday

Key Points

• REGENXBIO is set to report Q1 2026 results before the market on May 11, with analysts forecasting EPS of -$1.36 and $25.84M in revenue; the company’s earnings call is scheduled for May 15.
• The company recently missed estimates—reporting Q4 EPS of -$1.30 vs. -$1.01 expected and revenue of $30.34M versus $45.48M—and shows negative return on equity and net margin, with analysts projecting roughly - $2 EPS for the current and next fiscal year.
• Shares trade around $9.16 with a market cap of about $472.7M, while the Street’s consensus target is a much higher $27.50 (Moderate Buy)

REGENXBIO (NASDAQ:RGNX - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.36) per share and revenue of $25.8420 million for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 12:30 PM ET.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The firm had revenue of $30.34 million during the quarter, compared to analysts' expectations of $45.48 million. On average, analysts expect REGENXBIO to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

REGENXBIO Trading Up 0.4%

NASDAQ:RGNX traded up $0.04 during trading hours on Monday, hitting $9.16. The stock had a trading volume of 209,327 shares, compared to its average volume of 871,276. REGENXBIO has a 1-year low of $6.89 and a 1-year high of $16.19. The business has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $11.19. The company has a market cap of $472.74 million, a PE ratio of -2.45 and a beta of 1.12.

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, insider Steve Pakola sold 5,124 shares of the company's stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $10.35, for a total value of $53,033.40. Following the transaction, the insider owned 247,926 shares in the company, valued at approximately $2,566,034.10. This represents a 2.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 14.22% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On REGENXBIO

A number of hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC boosted its position in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock valued at $4,437,000 after purchasing an additional 594,161 shares during the last quarter. State Street Corp grew its position in REGENXBIO by 15.2% in the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company's stock worth $32,929,000 after acquiring an additional 301,858 shares in the last quarter. GSK plc acquired a new position in shares of REGENXBIO during the 4th quarter worth $3,909,000. Jane Street Group LLC increased its stake in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company's stock worth $2,961,000 after purchasing an additional 249,156 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in shares of REGENXBIO by 2,049.0% during the 2nd quarter. Squarepoint Ops LLC now owns 219,288 shares of the biotechnology company's stock valued at $1,800,000 after purchasing an additional 209,084 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RGNX has been the subject of a number of research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Morgan Stanley dropped their target price on shares of REGENXBIO from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, March 5th. Barclays initiated coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $37.00 target price on the stock. UBS Group reiterated an "overweight" rating and issued a $18.00 price target on shares of REGENXBIO in a research note on Tuesday, February 10th. Finally, HC Wainwright lowered their price objective on REGENXBIO from $32.00 to $30.00 and set a "buy" rating for the company in a report on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, REGENXBIO has an average rating of "Moderate Buy" and a consensus target price of $27.50.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.